Ex post
Ex post regulation governs outcomes that occur after the activity that is the subject of the regulation commences. In the context of FDA, this refers to companies being liable for harms caused to the public after drugs are commercially released; in the context of AI, it may refer to liability for harms arising as a result of the use of the AI product in question.